349 related articles for article (PubMed ID: 17870114)
1. Effect of alpha1-adrenoceptor antagonist exposure on prostate cancer incidence: an observational cohort study.
Harris AM; Warner BW; Wilson JM; Becker A; Rowland RG; Conner W; Lane M; Kimbler K; Durbin EB; Baron AT; Kyprianou N
J Urol; 2007 Nov; 178(5):2176-80. PubMed ID: 17870114
[TBL] [Abstract][Full Text] [Related]
2. Decreased risk of bladder cancer in men treated with quinazoline-based α1-adrenoceptor antagonists.
Martin FM; Harris AM; Rowland RG; Conner W; Lane M; Durbin E; Baron AT; Kyprianou N
Gene Ther Mol Biol; 2008; 12(2):253-258. PubMed ID: 20717483
[TBL] [Abstract][Full Text] [Related]
3. Quinazoline-derived alpha1-adrenoceptor antagonists induce prostate cancer cell apoptosis via an alpha1-adrenoceptor-independent action.
Benning CM; Kyprianou N
Cancer Res; 2002 Jan; 62(2):597-602. PubMed ID: 11809715
[TBL] [Abstract][Full Text] [Related]
4. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
Tahmatzopoulos A; Kyprianou N
Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
[TBL] [Abstract][Full Text] [Related]
5. Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin.
Keledjian K; Borkowski A; Kim G; Isaacs JT; Jacobs SC; Kyprianou N
Prostate; 2001 Jul; 48(2):71-8. PubMed ID: 11433417
[TBL] [Abstract][Full Text] [Related]
6. Alpha1-adrenoceptor antagonists radiosensitize prostate cancer cells via apoptosis induction.
Cuellar DC; Rhee J; Kyprianou N
Anticancer Res; 2002; 22(3):1673-9. PubMed ID: 12168853
[TBL] [Abstract][Full Text] [Related]
7. Anoikis induction by quinazoline based alpha 1-adrenoceptor antagonists in prostate cancer cells: antagonistic effect of bcl-2.
Keledjian K; Kyprianou N
J Urol; 2003 Mar; 169(3):1150-6. PubMed ID: 12576871
[TBL] [Abstract][Full Text] [Related]
8. Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis.
Kyprianou N; Benning CM
Cancer Res; 2000 Aug; 60(16):4550-5. PubMed ID: 10969806
[TBL] [Abstract][Full Text] [Related]
9. Doxazosin and terazosin suppress prostate growth by inducing apoptosis: clinical significance.
Kyprianou N
J Urol; 2003 Apr; 169(4):1520-5. PubMed ID: 12629407
[TBL] [Abstract][Full Text] [Related]
10. Relative cytotoxic potencies and cell death mechanisms of α1 -adrenoceptor antagonists in prostate cancer cell lines.
Forbes A; Anoopkumar-Dukie S; Chess-Williams R; McDermott C
Prostate; 2016 Jun; 76(8):757-66. PubMed ID: 26880388
[TBL] [Abstract][Full Text] [Related]
11. The Role of α1-Adrenoceptor Antagonists in the Treatment of Prostate and Other Cancers.
Batty M; Pugh R; Rathinam I; Simmonds J; Walker E; Forbes A; Anoopkumar-Dukie S; McDermott CM; Spencer B; Christie D; Chess-Williams R
Int J Mol Sci; 2016 Aug; 17(8):. PubMed ID: 27537875
[TBL] [Abstract][Full Text] [Related]
12. Reduction of prostate cancer incidence by naftopidil, an α1 -adrenoceptor antagonist and transforming growth factor-β signaling inhibitor.
Yamada D; Nishimatsu H; Kumano S; Hirano Y; Suzuki M; Fujimura T; Fukuhara H; Enomoto Y; Kume H; Homma Y
Int J Urol; 2013 Dec; 20(12):1220-7. PubMed ID: 23600973
[TBL] [Abstract][Full Text] [Related]
13. Effects of alpha(1)-adrenoceptor (alpha(1)-AR) antagonists on cell proliferation and apoptosis in the prostate: therapeutic implications in prostatic disease.
Kyprianou N; Chon J; Benning CM
Prostate Suppl; 2000; 9():42-6. PubMed ID: 11056502
[TBL] [Abstract][Full Text] [Related]
14. Alpha 1-adrenoceptor antagonists terazosin and doxazosin induce prostate apoptosis without affecting cell proliferation in patients with benign prostatic hyperplasia.
Chon JK; Borkowski A; Partin AW; Isaacs JT; Jacobs SC; Kyprianou N
J Urol; 1999 Jun; 161(6):2002-8. PubMed ID: 10332490
[TBL] [Abstract][Full Text] [Related]
15. Induction of apoptosis in the prostate by alpha1-adrenoceptor antagonists: a novel effect of "old" drugs.
Kyprianou N; Jacobs SC
Curr Urol Rep; 2000 Aug; 1(2):89-96. PubMed ID: 12084321
[TBL] [Abstract][Full Text] [Related]
16. No risk of drug-associated liver injury with alpha1-adrenoreceptor blocking agents in men with BPH: results from an observational study using the GPRD.
Clifford GM; Logie J; Farmer RD
Pharmacoepidemiol Drug Saf; 2005 Feb; 14(2):75-80. PubMed ID: 15386708
[TBL] [Abstract][Full Text] [Related]
17. Effect of terazosin on tissue vascularity and apoptosis in transitional cell carcinoma of bladder.
Tahmatzopoulos A; Lagrange CA; Zeng L; Mitchell BL; Conner WT; Kyprianou N
Urology; 2005 May; 65(5):1019-23. PubMed ID: 15882756
[TBL] [Abstract][Full Text] [Related]
18. Treatment with finasteride and prostate cancer survival.
Kjellman A; Friis S; Granath F; Gustafsson O; Sørensen HT; Akre O
Scand J Urol; 2013 Aug; 47(4):265-71. PubMed ID: 23137166
[TBL] [Abstract][Full Text] [Related]
19. The role of alpha-blockers in the management of prostate cancer.
Tahmatzopoulos A; Rowland RG; Kyprianou N
Expert Opin Pharmacother; 2004 Jun; 5(6):1279-85. PubMed ID: 15163273
[TBL] [Abstract][Full Text] [Related]
20. Apoptotic and proliferative index after Alpha-1-adrenoceptor antagonist and/or finasteride treatment in benign prostatic hyperplasia.
Erdoğru T; Ciftcioglu MA; Emreoglu I; Usta MF; Koksal T; Ozbilim G; Gulkesen KH; Baykara M
Urol Int; 2002; 69(4):287-92. PubMed ID: 12444285
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
